Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro - PubMed (original) (raw)
Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro
A Carano et al. J Clin Invest. 1990 Feb.
Abstract
Bisphosphonates are useful in treatment of disorders with increased osteoclastic activity, but the mechanism by which bisphosphonates act is unknown. We used cultures of chicken osteoclasts to address this issue, and found that 1-hydroxyethylidenediphosphonic acid (EHDP), dichloromethylidenediphosphonic acid (Cl2MDP), or 3-amino-1-hydroxypropylidene-1,1-diphosphonic acid (APD) all cause direct dose-dependent suppression of osteoclastic activity. Effects are mediated by bone-bound drugs, with 50% reduction of bone degradation occurring at 500 nM to 5 microM of the different agents. Osteoclastic bone-binding capacity decreased by 30-40% after 72 h of bisphosphonate treatment, despite maintenance of cell viability. Significant inhibition of bone resorption in each case is seen only after 24-72 h of treatment. Osteoclast activity depends on ATP-dependent proton transport. Using acridine orange as an indicator, we found that EHDP reduces proton accumulation by osteoclasts. However, inside-out plasma membrane vesicles from osteoclasts transport H+ normally in response to ATP in high concentrations of EHDP, Cl2MDP, or APD. This suggests that the bisphosphonates act as metabolic inhibitors. Bisphosphonates reduce osteoclastic protein synthesis, supporting this hypothesis. Furthermore, [3H]leucine incorporation by the fibroblast, which does not resorb bone, is also diminished by EHDP, Cl2MDP and APD except when co-cultured with bisphosphonate-binding bone particles. Thus, the resorption-antagonizing capacities of EHDP, Cl2MDP and APD reflect metabolic inhibition, with selectivity for the osteoclast resulting from high affinity binding to bone mineral.
Similar articles
- Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy.
Sato M, Grasser W. Sato M, et al. J Bone Miner Res. 1990 Jan;5(1):31-40. doi: 10.1002/jbmr.5650050107. J Bone Miner Res. 1990. PMID: 2106763 - The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
David P, Nguyen H, Barbier A, Baron R. David P, et al. J Bone Miner Res. 1996 Oct;11(10):1498-507. doi: 10.1002/jbmr.5650111017. J Bone Miner Res. 1996. PMID: 8889850 - Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group.
Boonekamp PM, Löwik CW, van der Wee-Pals LJ, van Wijk-van Lennep ML, Bijvoet OL. Boonekamp PM, et al. Bone Miner. 1987 Feb;2(1):29-42. Bone Miner. 1987. PMID: 3504722 - [Inhibitory effects of bisphosphonates on bone resorption].
Shinoda H. Shinoda H. Nihon Yakurigaku Zasshi. 1995 May;105(5):285-94. doi: 10.1254/fpj.105.285. Nihon Yakurigaku Zasshi. 1995. PMID: 7628780 Review. Japanese. - Antitumor effects of bisphosphonates.
Green JR. Green JR. Cancer. 2003 Feb 1;97(3 Suppl):840-7. doi: 10.1002/cncr.11128. Cancer. 2003. PMID: 12548584 Review.
Cited by
- The Effect of Alendronate on Osteoclastogenesis in Different Combinations of M-CSF and RANKL Growth Factors.
Hedvičáková V, Žižková R, Buzgo M, Rampichová M, Filová E. Hedvičáková V, et al. Biomolecules. 2021 Mar 16;11(3):438. doi: 10.3390/biom11030438. Biomolecules. 2021. PMID: 33809737 Free PMC article. - Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL.
Jang Y, Sohn HM, Ko YJ, Hyun H, Lim W. Jang Y, et al. Int J Mol Sci. 2021 Jan 4;22(1):434. doi: 10.3390/ijms22010434. Int J Mol Sci. 2021. PMID: 33406741 Free PMC article. - Biofunctionalization of titanium surfaces with alendronate and albumin modulates osteoblast performance.
Albano CS, Moreira Gomes A, da Silva Feltran G, da Costa Fernandes CJ, Trino LD, Zambuzzi WF, Lisboa-Filho PN. Albano CS, et al. Heliyon. 2020 Jul 21;6(7):e04455. doi: 10.1016/j.heliyon.2020.e04455. eCollection 2020 Jul. Heliyon. 2020. PMID: 32715131 Free PMC article. - Bisphosphonate-based nanocomposite hydrogels for biomedical applications.
Yuan W, Li Z, Xie X, Zhang ZY, Bian L. Yuan W, et al. Bioact Mater. 2020 Jun 22;5(4):819-831. doi: 10.1016/j.bioactmat.2020.06.002. eCollection 2020 Dec. Bioact Mater. 2020. PMID: 32637746 Free PMC article. Review. - Increased flux through the mevalonate pathway mediates fibrotic repair without injury.
Larson-Casey JL, Vaid M, Gu L, He C, Cai GQ, Ding Q, Davis D, Berryhill TF, Wilson LS, Barnes S, Neighbors JD, Hohl RJ, Zimmerman KA, Yoder BK, Longhini ALF, Hanumanthu VS, Surolia R, Antony VB, Carter AB. Larson-Casey JL, et al. J Clin Invest. 2019 Nov 1;129(11):4962-4978. doi: 10.1172/JCI127959. J Clin Invest. 2019. PMID: 31609245 Free PMC article.
References
- J Bone Miner Res. 1987 Apr;2(2):135-42 - PubMed
- J Clin Invest. 1989 Jan;83(1):227-33 - PubMed
- J Bone Miner Res. 1988 Apr;3(2):185-92 - PubMed
- Science. 1989 Aug 25;245(4920):855-7 - PubMed
- Science. 1969 Sep 19;165(3899):1262-4 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources